Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Management of hepatitis B virus infection, updated Swedish guidelines.

Westin J, Aleman S, Castedal M, Duberg AS, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R.

Infect Dis (Lond). 2020 Jan;52(1):1-22. doi: 10.1080/23744235.2019.1675903. Epub 2019 Oct 15.

PMID:
31613181
2.

Alcohol and drug use prior to liver transplantation: more common than expected in patients with non-alcoholic liver disease.

Schult A, Stokkeland K, Ericzon BG, Hultcrantz R, Franck J, Stål P, Castedal M.

Scand J Gastroenterol. 2019 Sep;54(9):1146-1154. doi: 10.1080/00365521.2019.1656772. Epub 2019 Aug 27.

PMID:
31453745
3.

The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease.

Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P.

Scand J Gastroenterol. 2019 Jun;54(6):746-752. doi: 10.1080/00365521.2019.1627580. Epub 2019 Jun 13.

PMID:
31190577
4.

No need to discontinue hepatitis C virus therapy at the time of liver transplantation.

Skoglund C, Lagging M, Castedal M.

PLoS One. 2019 Feb 22;14(2):e0211437. doi: 10.1371/journal.pone.0211437. eCollection 2019.

5.

Long-term survival and predictors of relapse and survival after liver transplantation for alcoholic liver disease.

Lindenger C, Castedal M, Schult A, Åberg F.

Scand J Gastroenterol. 2018 Dec;53(12):1553-1561. doi: 10.1080/00365521.2018.1536226.

PMID:
30678557
6.

Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation.

Castedal M, Skoglund C, Axelson C, Bennet W.

Scand J Gastroenterol. 2018 Jun;53(6):741-747. doi: 10.1080/00365521.2018.1463390. Epub 2018 Apr 24.

PMID:
29688072
7.

Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries.

Holmer M, Melum E, Isoniemi H, Ericzon BG, Castedal M, Nordin A, Aagaard Schultz N, Rasmussen A, Line PD, Stål P, Bennet W, Hagström H.

Liver Int. 2018 Nov;38(11):2082-2090. doi: 10.1111/liv.13751. Epub 2018 May 2.

PMID:
29630771
8.

Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study.

Lindström L, Jørgensen KK, Boberg KM, Castedal M, Rasmussen A, Rostved AA, Isoniemi H, Bottai M, Bergquist A.

Scand J Gastroenterol. 2018 Mar;53(3):297-304. doi: 10.1080/00365521.2017.1421705. Epub 2018 Jan 4.

PMID:
29301479
9.

Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation.

Majeed A, Castedal M, Arnelo U, Söderdahl G, Bergquist A, Said K.

Scand J Gastroenterol. 2018 Jan;53(1):56-63. doi: 10.1080/00365521.2017.1385840. Epub 2017 Oct 9.

PMID:
28990806
10.

Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.

Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Westin J; Swedish Consensus Group.

Infect Dis (Lond). 2017 Aug;49(8):561-575. doi: 10.1080/23744235.2017.1300682. Epub 2017 Mar 15. Review.

PMID:
28293974
11.

INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.

Castedal M, Segenmark M, Cederberg S, Skoglund C, Weiland O.

Scand J Gastroenterol. 2017 May;52(5):585-588. doi: 10.1080/00365521.2017.1283439. Epub 2017 Feb 13. Erratum in: Scand J Gastroenterol. 2017 Nov;52(11):i.

PMID:
28270038
12.

Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.

Norder H, Karlsson M, Mellgren Å, Konar J, Sandberg E, Lasson A, Castedal M, Magnius L, Lagging M.

J Clin Microbiol. 2016 Mar;54(3):549-55. doi: 10.1128/JCM.02343-15. Epub 2015 Dec 9.

13.

Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.

Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Josephson F; Swedish Consensus Group.

Infect Dis (Lond). 2016 Apr;48(4):251-261. doi: 10.3109/23744235.2015.1113438. Epub 2015 Dec 1. Review.

14.

Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report.

Waldenström J, Castedal M, Konar J, Karason K, Lagging M, Norder H.

J Med Case Rep. 2015 Aug 26;9:180. doi: 10.1186/s13256-015-0655-z.

15.

Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013.

Fosby B, Melum E, Bjøro K, Bennet W, Rasmussen A, Andersen IM, Castedal M, Olausson M, Wibeck C, Gotlieb M, Gjertsen H, Toivonen L, Foss S, Makisalo H, Nordin A, Sanengen T, Bergquist A, Larsson ME, Soderdahl G, Nowak G, Boberg KM, Isoniemi H, Keiding S, Foss A, Line PD, Friman S, Schrumpf E, Ericzon BG, Höckerstedt K, Karlsen TH.

Scand J Gastroenterol. 2015 Jun;50(6):797-808. doi: 10.3109/00365521.2015.1036359.

16.

Impact of cardiac dysfunction on health-related quality of life in cirrhotic liver transplant candidates.

Josefsson A, Fu M, Björnsson E, Castedal M, Kalaitzakis E.

Eur J Gastroenterol Hepatol. 2015 Apr;27(4):393-8. doi: 10.1097/MEG.0000000000000292.

PMID:
25874511
17.

Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.

Ackefors M, Castedal M, Dahlgard O, Verbaan H, Gjertsen H, Wernerson A, Weiland O.

Infect Dis (Lond). 2015 Apr;47(4):209-17. doi: 10.3109/00365548.2014.984322. Epub 2015 Feb 4.

PMID:
25650729
18.

Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study.

Åberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A, Bennet W, Olausson M, Line PD, Nordin A, Bergquist A, Boberg KM, Castedal M, Pedersen CR, Isoniemi H.

Hepatology. 2015 Feb;61(2):668-77. doi: 10.1002/hep.27538. Epub 2015 Jan 5.

PMID:
25266201
19.

Pre-transplant renal impairment predicts posttransplant cardiac events in patients with liver cirrhosis.

Josefsson A, Fu M, Björnsson E, Castedal M, Kalaitzakis E.

Transplantation. 2014 Jul 15;98(1):107-14. doi: 10.1097/01.TP.0000442781.31885.a2.

PMID:
24621533
20.

Gastrointestinal symptoms in patients with cirrhosis: a longitudinal study before and after liver transplantation.

Kalaitzakis E, Josefsson A, Castedal M, Henfridsson P, Bengtsson M, Andersson B, Björnsson E.

Scand J Gastroenterol. 2013 Nov;48(11):1308-16. doi: 10.3109/00365521.2013.836755. Epub 2013 Sep 25.

PMID:
24063547
21.

Are liver transplant recipients protected against hepatitis A and B?

Andersson D, Castedal M, Friman V.

Transplant Proc. 2013 Apr;45(3):1193-7. doi: 10.1016/j.transproceed.2012.10.012.

PMID:
23622657
22.
23.

Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis.

Kalaitzakis E, Josefsson A, Castedal M, Henfridsson P, Bengtsson M, Andersson B, Björnsson E.

Scand J Gastroenterol. 2013 May;48(5):577-84. doi: 10.3109/00365521.2013.777468. Epub 2013 Mar 4.

PMID:
23452072
24.

Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.

Jørgensen KK, Lindström L, Cvancarova M, Karlsen TH, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM.

Clin Gastroenterol Hepatol. 2013 May;11(5):517-23. doi: 10.1016/j.cgh.2012.12.027. Epub 2013 Jan 16.

PMID:
23333218
25.

[The transplant patient at the community health center and the emergency department].

Westman K, Castedal M, Bennet W, Kornhall B.

Lakartidningen. 2012 Sep 26-Oct 9;109(39-40):1762-5. Review. Swedish. No abstract available.

PMID:
23097886
26.

Impact of peri-transplant heart failure & left-ventricular diastolic dysfunction on outcomes following liver transplantation.

Josefsson A, Fu M, Allayhari P, Björnsson E, Castedal M, Olausson M, Kalaitzakis E.

Liver Int. 2012 Sep;32(8):1262-9. doi: 10.1111/j.1478-3231.2012.02818.x. Epub 2012 May 24.

PMID:
22621679
27.

Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.

Jørgensen KK, Lindström L, Cvancarova M, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM.

Scand J Gastroenterol. 2012 Sep;47(8-9):1021-9. doi: 10.3109/00365521.2012.685754. Epub 2012 May 14.

PMID:
22577871
28.

Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience.

Ydreborg M, Westin J, Lagging M, Castedal M, Friman S.

Scand J Gastroenterol. 2012 Jun;47(6):710-7. doi: 10.3109/00365521.2012.672592. Epub 2012 Mar 27.

PMID:
22452366
29.

Factors related to fatigue in patients with cirrhosis before and after liver transplantation.

Kalaitzakis E, Josefsson A, Castedal M, Henfridsson P, Bengtsson M, Hugosson I, Andersson B, Björnsson E.

Clin Gastroenterol Hepatol. 2012 Feb;10(2):174-81, 181.e1. doi: 10.1016/j.cgh.2011.07.029. Epub 2011 Aug 11.

PMID:
21839709
30.

Long-term follow-up of living liver donors.

Castedal M, Andersson M, Polanska-Tamborek D, Friman S, Olausson M, Fehrman-Ekholm I.

Transplant Proc. 2010 Dec;42(10):4449-54. doi: 10.1016/j.transproceed.2010.09.114.

PMID:
21168716
31.

Calculation and comparison of the model for end-stage liver disease (MELD) score in patients accepted for liver transplantation in 1999 and 2004.

Flodén A, Castedal M, Friman S, Olausson M, Backman L.

Transplant Proc. 2007 Mar;39(2):385-6.

PMID:
17362737
32.

Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation.

Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL; Swedish Internal Medicine Liver Club.

Hepatology. 2006 Dec;44(6):1572-80.

PMID:
17133469
33.

MELD [corrected] score in patients accepted for liver transplantation 1994 to 2004.

Flodén A, Castedal M, Friman S, Olausson M, Backman L.

Transplant Proc. 2006 Oct;38(8):2673-4. Erratum in: Transplant Proc. 2007 Jan-Feb;39(1):314.

PMID:
17098035
34.

Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis.

Castedal M, Felldin M, Bäckman L, Olausson M, Friman S.

Transplant Proc. 2005 Oct;37(8):3313-4.

PMID:
16298583
35.

Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism.

Björnsson E, Olsson J, Rydell A, Fredriksson K, Eriksson C, Sjöberg C, Olausson M, Bäckman L, Castedal M, Friman S.

Scand J Gastroenterol. 2005 Feb;40(2):206-16.

PMID:
15764153
36.

[Liver dialysis using MARS in acute hepatic failure. Promising results in a pilot setting].

Felldin M, Friman S, Olausson M, Bäckman L, Castedal M, Larsson B, Henriksson BA, Siewert-Delle A.

Lakartidningen. 2003 Nov 20;100(47):3836-8, 3841. Swedish.

PMID:
14719235
37.

Interlaboratory differences in method for analysis of manometry explain discrepancies in studies of duodenal phase III peristalsis.

Bjornsson E, Castedal M, Abrahamsson H.

Neurogastroenterol Motil. 2003 Jun;15(3):331-3; author reply 335. No abstract available.

PMID:
12787343
38.

Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.

Castedal M, Siewert-Delle A, Olausson M, Friman S.

Transplant Proc. 2003 Mar;35(2):820-1. No abstract available.

PMID:
12644153
39.

Mycophenolate mofetil in primary biliary cirrhosis.

Castedal M, Olsson R.

Hepatology. 2002 Nov;36(5):1297. No abstract available.

PMID:
12395345
40.

High-resolution analysis of the duodenal interdigestive phase III in humans.

Castedal M, Abrahamsson H.

Neurogastroenterol Motil. 2001 Oct;13(5):473-81.

PMID:
11696109
41.

Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)].

Simrén M, Castedal M, Svedlund J, Abrahamsson H, Björnsson E.

Dig Dis Sci. 2000 Nov;45(11):2151-61. Erratum in: Dig Dis Sci 2001 Jun;46(6):1352.

PMID:
11215731
42.

Infectious agents and primary biliary cirrhosis.

Nilsson HO, Taneera J, Castedal M, Wadström T, Olsson R.

J Hepatol. 2000 Aug;33(2):342-3. No abstract available.

PMID:
10952256
43.

Scintigraphic assessment of interdigestive duodenogastric reflux in humans: distinguishing between duodenal and biliary reflux material.

Castedal M, Björnsson E, Gretarsdottir J, Fjälling M, Abrahamsson H.

Scand J Gastroenterol. 2000 Jun;35(6):590-8.

PMID:
10912658
44.

Effects of midazolam on small bowel motility in humans.

Castedal M, Björnsson E, Abrahamsson H.

Aliment Pharmacol Ther. 2000 May;14(5):571-7.

46.

Detection of Helicobacter in the liver of patients with chronic cholestatic liver diseases.

Nilsson HO, Castedal M, Olsson R, Wadström T.

J Physiol Pharmacol. 1999 Dec;50(5):875-82.

PMID:
10695566
47.

Postprandial peristalsis in the human duodenum.

Castedal M, Björnsson E, Abrahamsson H.

Neurogastroenterol Motil. 1998 Jun;10(3):227-33.

PMID:
9659666
48.

Fulminant hepatic failure associated with dicoumarol therapy.

Castedal M, Aldenborg F, Olsson R.

Liver. 1998 Feb;18(1):67-9.

PMID:
9548270
49.

Duodenal juxtapyloric retroperistalsis in the interdigestive state in humans.

Castedal M, Björnsson E, Abrahamsson H.

Scand J Gastroenterol. 1997 Aug;32(8):797-804.

PMID:
9282972
50.

[Ascites--a diagnostic and therapeutic challenge].

Castedal M, Saldeen K, Olsson R.

Lakartidningen. 1996 Feb 28;93(9):784-8. Swedish. No abstract available.

PMID:
8656891

Supplemental Content

Loading ...
Support Center